165 related articles for article (PubMed ID: 11577167)
1. Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Lakhani SR
Mol Pathol; 2001 Oct; 54(5):281-4. PubMed ID: 11577167
[TBL] [Abstract][Full Text] [Related]
2. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
3. Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.
Lishman SC; Lakhani SR
Histopathology; 1999 Sep; 35(3):195-200. PubMed ID: 10469210
[TBL] [Abstract][Full Text] [Related]
4. [Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations].
Dauplat MM; Penault-Llorca F
Bull Cancer; 2004 Dec; 91 Suppl 4():S205-10. PubMed ID: 15899609
[TBL] [Abstract][Full Text] [Related]
5. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
6. Lobular neoplasia.
King TA; Reis-Filho JS
Surg Oncol Clin N Am; 2014 Jul; 23(3):487-503. PubMed ID: 24882347
[TBL] [Abstract][Full Text] [Related]
7. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
9. Molecular and biologic markers of premalignant lesions of human breast.
Krishnamurthy S; Sneige N
Adv Anat Pathol; 2002 May; 9(3):185-97. PubMed ID: 11981114
[TBL] [Abstract][Full Text] [Related]
10. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
11. PML protein expression in hereditary and sporadic breast cancer.
Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
13. Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Warmoes M; Lam SW; van der Groep P; Jaspers JE; Smolders YH; de Boer L; Pham TV; Piersma SR; Rottenberg S; Boven E; Jonkers J; van Diest PJ; Jimenez CR
Oncotarget; 2016 Sep; 7(39):63537-63548. PubMed ID: 27566577
[TBL] [Abstract][Full Text] [Related]
14. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer.
Mastracci TL; Boulos FI; Andrulis IL; Lam WL
Breast Cancer Res; 2007; 9(6):215. PubMed ID: 18036272
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
Viacava P; Naccarato AG; Bocci G; Fanelli G; Aretini P; Lonobile A; Evangelista G; Montruccoli G; Bevilacqua G
J Pathol; 2004 Oct; 204(2):140-6. PubMed ID: 15376259
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
17. The spectrum of 67-kD laminin receptor expression in breast carcinoma progression.
Viacava P; Naccarato AG; Collecchi P; Ménard S; Castronovo V; Bevilacqua G
J Pathol; 1997 May; 182(1):36-44. PubMed ID: 9227340
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.
Hoogerbrugge N; Bult P; de Widt-Levert LM; Beex LV; Kiemeney LA; Ligtenberg MJ; Massuger LF; Boetes C; Manders P; Brunner HG
J Clin Oncol; 2003 Jan; 21(1):41-5. PubMed ID: 12506168
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Vogel VG
Menopause; 2008; 15(4 Suppl):782-9. PubMed ID: 18596599
[TBL] [Abstract][Full Text] [Related]
20. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
